-
Emisphere Receives Notice of Results From Collaborator's Proof of Concept Study for Oral PTH for the Treatment of Postmenopausal Osteoporosis
Friday, June 17, 2011 - 8:35am | 167Emisphere Technologies, Inc. (OTC: EMIS) announced today that Novartis informed Emisphere of the results of its recently completed Proof of Concept study for an oral PTH1-34 using Emisphere's Eligen® Technology in post-menopausal women with osteoporosis or osteopenia. Novartis informed Emisphere...
-
Watson Confirms Court Decision Rejecting Teva's Motion to Prevent Launch of Generic SEASONIQUE
Friday, June 17, 2011 - 7:55am | 116Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States District Court for the District of Nevada denied Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction and request for a temporary restraining order preventing Watson's launch of generic SEASONIQUE® (...
-
Watson's Nabumetone Tablets Receive FDA Approval
Friday, June 17, 2011 - 7:30am | 79Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for Nabumetone Tablets USP, 500 mg and 750 mg. Watson expects to launch the product shortly. Nabumetone had total U.S...
-
A Peek Into The Market Before The Trading Starts
Friday, June 17, 2011 - 7:23am | 409Pre-open movers US stock futures are higher this morning. Futures on the Dow Jones Industrial Average gained 75 points to 11,974.00 and futures on the S&P 500 stock index rose 9.10 points to 1,272.60. Nasdaq 100 futures surged 13.25 points to 2,208.75. A Peek Into Global Markets Most Asian...
-
VIVUS Announces Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
Friday, June 17, 2011 - 7:00am | 121VIVUS, Inc. (Nasdaq: VVUS) today announced that the positive results from REVIVE-RP (TA-303), a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction,will be presented this afternoon at the 2011 Cancer Survivorship...
-
Rodman & Renshaw Maintains Market Perform on Catalyst Pharmaceutical Partners
Friday, June 17, 2011 - 6:00am | 139Rodman & Renshaw maintained its Market Perform rating on Catalyst Pharmaceutical Partners (NASDAQ: CPRX). In a research report published today, Rodman & Renshaw stressed it remains cautiously optimistic about the performance of some of Catalyst's new drugs. In the report, Rodman &...
-
Options Brief: Elan Corporation, plc
Thursday, June 16, 2011 - 3:25pm | 87Shares of Elan Corporation, plc (NYSE: ELN) are lower on the session by 6.07%, trading at $10.05. Overall call volume is now running at 2.07x the daily average, with 26% of all calls traded being purchases on the offer. 8,931 contracts have traded on the session so far. Elan Corporation, plc is...
-
Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Efficacy Results Evaluating CPP-115 for the Treatment of Infantile Spasms
Thursday, June 16, 2011 - 3:03pm | 203Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced initial positive efficacy results from an investigator sponsored study of CPP-115 in an animal model of infantile spasms. In this study, CPP-115 significantly reduced observed spasms for three times longer than vigabatrin (the...
-
Bristol-Myers Squibb Announces FDA Approves NULOJIX
Thursday, June 16, 2011 - 2:49pm | 114Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab...
-
Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Thursday, June 16, 2011 - 10:50am | 120Reata Pharmaceuticals, Inc. and Abbott (NYSE: ABT) announced today the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes. The trial, known as BEACON, is the first multinational,...
-
Generex Provides Update on Generex Oral-lyn Clinical & Regulatory Program
Thursday, June 16, 2011 - 9:19am | 224Generex Biotechnology Corporation (OTC: GNBT) today issued a synopsis of the update on the clinical and regulatory program for Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, provided at the annual meeting of the Company's stockholders held in New York City on June 8,...
-
Sanofi Enters Into Research Collaboration With Audion Therapeutics to Develop Potential Treatments for Hearing Loss
Thursday, June 16, 2011 - 8:08am | 47Sanofi (NYSE: SNY) announced today that it has entered into a two-year research collaboration with the biopharmaceutical company Audion Therapeutics to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach.
-
Jefferies Comments On ViroPharma's Cinryze Approval In Europe
Thursday, June 16, 2011 - 8:03am | 116According to Jefferies, VitoPharma (NASDAQ: VPHM) announced that the European Medicines Agency approved Cinryze in Europe for the treatment of hereditary angioedema (HAE). Jefferies said that it remains confident in $400m+ U.S. Cinryze prophylactic HAE sales by 2015. “Cetor is only selling in a...
-
Goldman Sachs Maintains Buy on Johnson & Johnson
Thursday, June 16, 2011 - 8:00am | 112Goldman Sachs is out with its report today on Johnson & Johnson (NYSE: JNJ), maintaining Buy. In a note to clients, Goldman Sachs writes, "We continue to see JNJ as the best underappreciated new product story in Pharma, with the only accelerating earnings trajectory over the next three years...
-
Citi Reports On FDA Approval For BMY
Thursday, June 16, 2011 - 7:39am | 162Citi is maintaining its Buy rating and its $30 price target on Bristol-Myers Squibb (NYSE: BMY) following the FDA's approval of the company's Nulogix. In its report, Citi writes, “The FDA approved Nulogix (belatacept) for the prevention of kidney transplant rejection as a result of the company...